What You Ought to Know
– Topos Bio has emerged from stealth with $10.5M in seed funding to resolve one of the vital persistent challenges in medication: focusing on intrinsically disordered proteins (IDPs). The seed funding was led by Boldstart, Threshold, and Neo, with participation from notable angel buyers together with Dara Khosrowshahi (CEO of Uber) and Naveen Rao (CEO of Unconventional AI).
– Whereas conventional fashions like AlphaFold deal with static constructions, Topos Bio’s basis mannequin, Topos-1, captures hundreds of thousands of dynamic fluctuations, outperforming each main protein mannequin in benchmarking exams and opening a brand new therapeutic class for Alzheimer’s, Parkinson’s, and aggressive cancers.
The Downside: Why One-Third of the Proteome is ‘Undruggable’
Conventional drug discovery is constructed on the “lock-and-key” mannequin, which requires steady, 3D binding pockets. Nonetheless, IDPs—which drive a number of the world’s most devastating ailments—quickly fluctuate by means of hundreds of thousands of shapes, leaving conventional medication with nowhere to anchor.
Topos-1 represents a paradigm shift by modeling protein dynamics as ensembles moderately than static snapshots. This permits the platform to establish “binding alternatives” inside dynamic constructions that have been beforehand invisible to computational instruments.
The Benchmarking Breakthrough: Topos-1 vs. The Giants
In a know-how report launched alongside the funding, Topos Bio demonstrated that its Topos-1 basis mannequin outperformed the trade’s heaviest hitters:
- AlphaFold (Google DeepMind): Surpassed in dealing with the dynamic complexity of disordered areas.
- Chai & Boltz: Outperformed throughout a broad benchmarking suite targeted on IDP-specific challenges.
Many “AI-only” biotech companies fail as a result of their predictions don’t survive a moist lab. Topos Bio differentiates itself by means of an built-in moist lab that constantly refines mannequin accuracy with real-world experimental knowledge. Led by Amir Khosrowshahi (former CTO of Intel AI) and Ryan Zarcone, the workforce has the technical pedigree—on the intersection of physics and AI—to deal with the high-stakes complexity of protein ensembles.
“Disordered proteins characterize one of many final main frontiers in drug discovery – they’re central to devastating ailments however almost unimaginable to focus on with current strategies,” stated Ryan Zarcone, co-founder and CEO of Topos Bio. “Our platform tackles this by modeling protein dynamics as ensembles moderately than static constructions. This strategy permits rational drug design and opens up a completely new class of beforehand undruggable biology.”
Strategic Collaboration: The Gladstone Partnership
The partnership with Gladstone Institutes (led by Dr. Steven Finkbeiner) is an enormous validation sign combining Gladstone’s superior imaging and illness modeling with Topos-1’s computational insights. The workforce is taking a step towards discovering modulators that may really cross the translational hole from lab to clinic.
